Envoy Medical, Inc. (COCH) - Form 8-K Summary
Business Context and Reporting Period
Envoy Medical, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on August 10, 2026. The filing serves to announce the Company's financial results for the fiscal quarter ended June 30, 2026. The Company's Class A Common Stock and Redeemable Warrants trade on The Nasdaq Stock Market LLC under the symbols COCH and COCHW, respectively.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a press release (Exhibit 99.1) containing the detailed financial results for the quarter ended June 30, 2026, but the data itself is not embedded in the provided 8-K text.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The document functions as a notification of the release of quarterly results rather than a detailed comparative analysis.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished in Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated into any Securities Act filings. No specific guidance, outlook, management commentary, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for the quarter ended June 30, 2026.
- Verify the status of the Company's emerging growth company designation and any related accounting election impacts.
- Confirm the exercise price of the Redeemable Warrants ($11.50 per share) and their current trading status on Nasdaq.
- Check for any subsequent updates regarding the Interim Chief Financial Officer, Robert Potashnick, who signed this report.